Phosphorylation of LRRK2 by casein kinase 1α regulates trans-Golgi clustering via differential interaction with ARHGEF7

Nature Communications

Volumn 5, Issue , 2014, Pages

  Chia, Ruth ^a,c   Haddock, Sara ^a   Beilina, Alexandra ^a   Rudenko, Iakov N ^a   Mamais, Adamantios ^a   Kaganovich, Alice ^a   Li, Yan ^b   Kumaran, Ravindran ^a   Nalls, Michael A ^a   Cookson, Mark R ^a  

^a Laboratory of Membrane Biochemistry and Biophysics   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN KINASE IALPHA; GUANINE NUCLEOTIDE EXCHANGE FACTOR; LEUCINE RICH REPEAT KINASE 2; SMALL INTERFERING RNA; 4-(4-(2,3-DIHYDROBENZO(1,4)DIOXIN-6-YL)-5-PYRIDIN-2-YL-1H-IMIDAZOL-2-YL)BENZAMIDE; ARHGEF7 PROTEIN, HUMAN; BENZAMIDE DERIVATIVE; IC 261; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; LRRK2 PROTEIN, HUMAN; MEMBRANE PROTEIN; PHLOROGLUCINOL; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR; TGOLN2 PROTEIN, HUMAN;

CELL ORGANELLE; CLUSTER ANALYSIS; DISEASE PREVALENCE; ENZYME ACTIVITY; PHOSPHORUS; PHYSIOLOGY; PROTEIN;

ACTIN POLYMERIZATION; ADULT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTOPHOSPHORYLATION; BRAIN CELL CULTURE; BRAIN SLICE; CELL LYSATE; CELLULAR DISTRIBUTION; CORPUS STRIATUM; DEPHOSPHORYLATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IMMUNOREACTIVITY; MOUSE; NEWBORN; NONHUMAN; PHENOTYPE; PLEIOTROPY; PROTEIN PROTEIN INTERACTION; SEQUENCE ANALYSIS; TRANS GOLGI NETWORK; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN CORTEX; C57BL MOUSE; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; KNOCKOUT MOUSE; METABOLISM; NERVE CELL; PHOSPHORYLATION; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION;

ANIMALS; BENZAMIDES; CASEIN KINASE IALPHA; CEREBRAL CORTEX; CORPUS STRIATUM; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; IMIDAZOLES; INDOLES; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURONS; PHLOROGLUCINOL; PHOSPHORYLATION; PRIMARY CELL CULTURE; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RHO GUANINE NUCLEOTIDE EXCHANGE FACTORS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANS-GOLGI NETWORK;

EID: 84923380012     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6827     Document Type: Article

References (43)

1. Paisán-Ruiz, C., Lewis, P. A. & Singleton, A. B. LRRK2: cause, risk, and mechanism. J. Park. Dis. 3, 85-103 (2013).
2. Mata, I. F., Wedemeyer, W. J., Farrer, M. J., Taylor, J. P. & Gallo, K. A. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci. 29, 286-293 (2006).
3. Greggio, E. et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 23, 329-341 (2006).
4. Greggio, E. & Cookson, M. R. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro. 1 (2009).
5. Daniels, V. et al. Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J. Neurochem. 116, 304-315 (2011).
6. Lewis, P. A. et al. The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem. Biophys. Res. Commun. 357, 668-671 (2007).
7. Kett, L. R. & Dauer, W. T. Leucine-rich repeat kinase 2 for beginners: six key questions. Cold Spring Harb. Perspect. Med. 2, a009407 (2012).
8. Gloeckner, C. J. et al. Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2. J. Proteome Res. 9, 1738-1745 (2010).
9. Dzamko, N. et al. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem. J. 430, 405-413 (2010).
10. Sheng, Z. et al. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci. Transl. Med. 4, 164ra161 (2012).
11. Lobbestael, E., Baekelandt, V. & Taymans, J. M. Phosphorylation of LRRK2: from kinase to substrate. Biochem. Soc. Trans. 40, 1102-1110 (2012).
12. Deng, X. et al. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat. Chem. Biol. 7, 203-205 (2011).
13. Doggett, E. A., Zhao, J., Mork, C. N., Hu, D. & Nichols, R. J. Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition. J. Neurochem. 120, 37-45 (2012).
14. Li, X. et al. Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease. PLoS ONE 6, e17153 (2011).
15. Rudenko, I. N. et al. The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation. Biochem. J. 446, 99-111 (2012).
16. Lobbestael, E. et al. Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle. Biochem. J. 456, 119-128 (2013).
17. Nichols, R. J. et al. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem. J. 430, 393-404 (2010).
18. Beilina, A. et al. Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc. Natl Acad. Sci. USA 111, 2626-2631 (2014).
19. MacLeod, D. A. et al. RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. Neuron 77, 425-439 (2013).
20. Civiero, L. et al. Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers. PLoS ONE 7, e43472 (2012).
21. Taymans, J.-M., Gao, F. & Baekelandt, V. Metabolic labeling of leucine rich repeat kinases 1 and 2 with radioactive phosphate. J. Vis. Exp. JoVE e50523 (2013).
22. Nurse, P. & Thuriaux, P. Regulatory genes controlling mitosis in the fission yeast Schizosaccharomyces pombe. Genetics 96, 627-637 (1980).
23. Luerman, G. C. et al. Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J. Neurochem. 128, 561-576 (2014).
24. Haebig, K. et al. ARHGEF7 (Beta-PIX) acts as guanine nucleotide exchange factor for leucine-rich repeat kinase 2. PLoS ONE 5, e13762 (2010).
25. Anitei, M. et al. Protein complexes containing CYFIP/Sra/PIR121 coordinate Arf1 and Rac1 signalling during clathrin-AP-1-coated carrier biogenesis at the TGN. Nat. Cell Biol. 12, 330-340 (2010).
26. Taymans, J. M. et al. LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding. PLoS ONE 6, e23207 (2011).
27. Liu, M., Dobson, B., Glicksman, M. A., Yue, Z. & Stein, R. L. Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities. Biochemistry (Mosc.) 49, 2008-2017 (2010).
28. Chan, D., Citro, A., Cordy, J. M., Shen, G. C. & Wolozin, B. Rac1 protein rescues neurite retraction caused by G2019S Leucine-rich repeat kinase 2 (LRRK2). J. Biol. Chem. 286, 16140-16149 (2011).
29. Shin, N. et al. LRRK2 regulates synaptic vesicle endocytosis. Exp. Cell Res. 314, 2055-2065 (2008).
30. Dodson, M. W., Zhang, T., Jiang, C., Chen, S. & Guo, M. Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning. Hum. Mol. Genet. 21, 1350-1363 (2012).
31. Gomez-Suaga, P. et al. LRRK2 delays degradative receptor trafficking by impeding late endosomal budding through decreasing Rab7 activity. Hum. Mol. Genet. (2014doi:10.1093/hmg/ddu395.
32. Dusonchet, J. et al. A Parkinson's disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity. Hum. Mol. Genet. 23, 4887-4905 (2014).
33. Sabbatini, M. E., Bi, Y., Ji, B., Ernst, S. A. & Williams, J. A. CCK activates RhoA and Rac1 differentially through G 13 and G q in mouse pancreatic acini. AJP Cell Physiol. 298, C592-C601 (2010).
34. Xiong, Y., Yuan, C., Chen, R., Dawson, T. M. & Dawson, V. L. ArfGAP1 is a GTPase activating protein for LRRK2: reciprocal regulation of ArfGAP1 by LRRK2. J. Neurosci. 32, 3877-3886 (2012).
35. Stafa, K. et al. GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1. PLoS Genet. 8, e1002526 (2012).
36. Baird, D., Feng, Q. & Cerione, R. A. The cool-2/a-pix protein mediates a Cdc42-Rac signaling cascade. Curr. Biol. 15, 1-10 (2005).
37. Anitei, M. & Hoflack, B. Bridging membrane and cytoskeleton dynamics in the secretory and endocytic pathways. Nat. Cell Biol. 14, 11-19 (2011).
38. Wang, S. et al. A role of Rab29 in the integrity of the trans-golgi network and retrograde trafficking of mannose-6-phosphate receptor. PLoS ONE 9, e96242 (2014).
39. Stein, M.-P., Müller, M. P. & Wandinger-Ness, A. Bacterial pathogens commandeer Rab GTPases to establish intracellular niches: co-opting Rab protein function. Traffic 13, 1565-1588 (2012).
40. McCoy, M. K., Kaganovich, A., Rudenko, I. N., Ding, J. & Cookson, M. R. Hexokinase activity is required for recruitment of parkin to depolarized mitochondria. Hum. Mol. Genet. 23, 145-156 (2014).
41. Parisiadou, L. et al. Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J. Neurosci. Off. J. Soc. Neurosci. 29, 13971-13980 (2009).
42. Ubersax, J. A. & Ferrell, Jr J. E. Mechanisms of specificity in protein phosphorylation. Nat. Rev. Mol. Cell Biol. 8, 530-541 (2007).
43. Marin, O. et al. A noncanonical sequence phosphorylated by casein kinase 1 in beta-catenin may play a role in casein kinase 1 targeting of important signaling proteins. Proc. Natl Acad. Sci. USA 100, 10193-10200 (2003).